Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T-cells for treatment of multiple myeloma
Sign Up to like & getrecommendations! Published in 2020 at "Leukemia"
DOI: 10.1038/s41375-020-0951-5
Abstract: Chimeric antigen receptor (CAR) T-cell therapy remains limited to select centers that can carefully monitor adverse events. To broaden use of CAR T cells in community clinics and in a frontline setting, we developed a… read more here.
Keywords: treatment multiple; myeloma; multiple myeloma; car cells ... See more keywords
Development of an Allogeneic Anti-Bcma T Cell Therapy Utilizing a Novel Dimeric Antigen Receptor (DAR) Structure
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2019-131892
Abstract: Background: Multiple myeloma remains an incurable malignancy of plasma cells. Adoptive transfer of chimeric antigen receptor (CAR)-expressing T cells is a promising new therapy for hematologic malignancies. B-cell maturation antigen (BCMA) is a protein that… read more here.
Keywords: anti bcma; equity ownership; dar;
Serum Bcma May Interfere with Anti-Bcma-CAR-Transduced T Cells or Other Anti-Bcma Antibody-Based Immunotherapy in Multiple Myeloma
Sign Up to like & getrecommendations! Published in 2017 at "Blood"
DOI: 10.1182/blood.v130.suppl_1.4413.4413
Abstract: Introduction: CAR T cell-based immunotherapy has shown clinical activity in a variety of B-cell malignancies. Specifically, the engineered CAR-transduced T cells targeting B-cell maturation antigen (BCMA) on multiple myeloma (MM) have shown promising activity for… read more here.
Keywords: bcma; serum; bcma antibody; anti bcma ... See more keywords
Role of Anti-B-Cell Maturation Antigen (BCMA) in the Management of Multiple Myeloma
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14143507
Abstract: Simple Summary Multiple myeloma is the most prevalent hematological cancer, and further treatments for this disease are required. Despite progress in the development of treatment regimens, multiple myeloma is still an incurable disease because of… read more here.
Keywords: cell; anti bcma; myeloma; treatment ... See more keywords
Non-Conventional Allogeneic Anti-BCMA Chimeric Antigen Receptor-Based Immune Cell Therapies for Multiple Myeloma Treatment
Sign Up to like & getrecommendations! Published in 2023 at "Cancers"
DOI: 10.3390/cancers15030567
Abstract: Simple Summary Multiple Myeloma (MM) is the second most common hematological malignancy in the world. The current two US Food and Drug Administration (FDA)-approved anti-BCMA chimeric antigen receptor (CAR)-T cells therapies for MM treatment rely… read more here.
Keywords: cell; anti bcma; car; treatment ... See more keywords